P/E ratio for MedCap (MCAP.ST)
P/E ratio as of April 2025 (TTM): 31.4
According to MedCap's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 31.3766. At the end of 2023 the company had a P/E ratio of 29.1.
P/E ratio history for MedCap from 2009 to 2024
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2023 | 29.1 | 6.17% |
| 2022 | 27.4 | 0.07% |
| 2021 | 27.4 | -49.99% |
| 2020 | 54.8 | 57.59% |
| 2019 | 34.8 | |
| 2017 | 225 | 1006.56% |
| 2016 | 20.3 | -57.79% |
| 2015 | 48.2 | 115.33% |
| 2014 | 22.4 | 49.12% |
| 2013 | 15.0 | -15.63% |
| 2012 | 17.8 | 14.08% |
| 2011 | 15.6 | -42.71% |
| 2010 | 27.2 | |
| 2008 | -32.3 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.